Výsledky vyhledávání

Akademický článek

Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma

Autor: Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit

Publikováno v: Liver Cancer, Pp 1-10 (2024)

Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monother

Externí odkaz: https://doaj.org/article/060277f2d7054affa161c9c60698ca95

Zobrazit plný text záznamu

Akademický článek

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Autor: Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins

Publikováno v: Translational Oncology, Vol 49, Iss , Pp 102073- (2024)

Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible

Externí odkaz: https://doaj.org/article/80c2e8e9bf2e4172bafb263c57f5769f

Zobrazit plný text záznamu

Akademický článek

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)

In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos

Externí odkaz: https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1

Zobrazit plný text záznamu

Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

Autor: Debbie O’Reilly, Lisa D. Eli, Alvin Wong, John Crown, Denis M. Collins

Publikováno v: Cancer Research. 83:P6-12

Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::692f32f78c34a4001c917b139f616e51
https://doi.org/10.1158/1538-7445.sabcs22-p6-12-09

Zobrazit plný text záznamu

Akademický článek

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)

Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea

Externí odkaz: https://doaj.org/article/cf5037433d854254a48613d85af66f77

Zobrazit plný text záznamu

Abstract P2-13-39: Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models

Autor: Amira F Mahdi, Neil T Conlon, Lisa D Eli, Irmina Diala, John Crown, Denis Collins

Publikováno v: Cancer Research. 82:P2-13

Background: HER2-positive (+) breast cancer (BC) represents a significant clinical burden due to an aggressive phenotype and propensity for brain metastasis. Up to 70 % of HER2+ BCs are also oestrogen receptor (ER)-positive, with receptor crosstalk o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b95521ea04f1f44e06868091b052c6da
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-39

Zobrazit plný text záznamu

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Autor: Debbie O'Reilly, Nicola Gaynor, Neil Conlon, Irmina Diala, Lisa D Eli, John Crown, Denis M Collins

Publikováno v: Cancer Research. 82:P2-13

Introduction: Treatment strategies for HER2+ breast cancer (BC) involves first line treatment with the monoclonal antibody trastuzumab, however resistance to treatment can occur. The pan-HER tyrosine kinase inhibitor neratinib is an approved adjuvant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc580fc650c861cc273bda4a949dcca5
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-28

Zobrazit plný text záznamu

Akademický článek

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Autor: Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno

Publikováno v: Biomedicines, Vol 9, Iss 7, p 740 (2021)

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identi

Externí odkaz: https://doaj.org/article/cedd88ae516042b3b4bd35ba6d3e15c2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání